These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 17895339)
21. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Bröker M; Veitch K Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306 [TBL] [Abstract][Full Text] [Related]
22. Meningococcal disease: risk for international travellers and vaccine strategies. Wilder-Smith A Travel Med Infect Dis; 2008 Jul; 6(4):182-6. PubMed ID: 18571105 [TBL] [Abstract][Full Text] [Related]
23. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Pace D Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946 [TBL] [Abstract][Full Text] [Related]
24. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Pollard AJ; Green C; Sadarangani M; Snape MD Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919 [No Abstract] [Full Text] [Related]
25. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. Papaevangelou V; Spyridis N Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896 [TBL] [Abstract][Full Text] [Related]
29. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines. Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679 [TBL] [Abstract][Full Text] [Related]
30. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. de Greeff SC; de Melker HE; Spanjaard L; Schouls LM; van Derende A Pediatr Infect Dis J; 2006 Jan; 25(1):79-80. PubMed ID: 16395110 [TBL] [Abstract][Full Text] [Related]
31. Meningococcal conjugate vaccine in adolescents and children. Pichichero ME Clin Pediatr (Phila); 2005; 44(6):479-89. PubMed ID: 16015394 [TBL] [Abstract][Full Text] [Related]
32. Advances towards the prevention of meningococcal B disease: a multidimensional story. Roderick M; Finn A J Infect; 2014 Jan; 68 Suppl 1():S76-82. PubMed ID: 24139188 [TBL] [Abstract][Full Text] [Related]
33. [Meningococcal vaccines: from polysaccharide to conjugate vaccines]. Cohen R; Levy C Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368 [TBL] [Abstract][Full Text] [Related]
34. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Hill DM; Lucidarme J; Gray SJ; Newbold LS; Ure R; Brehony C; Harrison OB; Bray JE; Jolley KA; Bratcher HB; Parkhill J; Tang CM; Borrow R; Maiden MC Lancet Infect Dis; 2015 Dec; 15(12):1420-8. PubMed ID: 26515523 [TBL] [Abstract][Full Text] [Related]
35. Meningococcal vaccine against serogroups A, C, Y and W-135: new preparation. Encouraging immunogenicity studies. Prescrire Int; 2002 Apr; 11(58):35-8. PubMed ID: 11987309 [TBL] [Abstract][Full Text] [Related]
36. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725 [TBL] [Abstract][Full Text] [Related]
37. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Villena R; Valenzuela MT; Bastías M; Santolaya ME Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728 [TBL] [Abstract][Full Text] [Related]
38. Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI) Can Commun Dis Rep; 2007 May; 33(ACS-3):1-23. PubMed ID: 17520774 [No Abstract] [Full Text] [Related]
39. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078 [TBL] [Abstract][Full Text] [Related]
40. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]